K36 Therapeutics, Inc.
Clinical trials sponsored by K36 Therapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for tough prostate cancer? early trial launches Results expected Sep 2027 (estimated)
-
New pill takes aim at Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called KTX-1001 in people with multiple myeloma that has returned or not responded to prior treatments. The drug works by blocking a protein that helps myeloma cells grow. The study will enroll 165 adults and will also test K…
Phase 1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug called KTX-2001, alone or with another drug (darolutamide), in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The main goals are to check safety, find the right dose, and …
Phase 1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC